Silo Pharma, Inc.
$0.67
▲
0.49%
2026-04-21 09:25:01
silopharma.com
NCM: SILO
Explore Silo Pharma, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$8.38 M
Current Price
$0.67
52W High / Low
$1.19 / $0.22
Stock P/E
—
Book Value
$0.47
Dividend Yield
—
ROCE
-61.55%
ROE
-74.57%
Face Value
—
EPS
$-0.5
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
3
Beta
0.59
Debt / Equity
—
Current Ratio
11.36
Quick Ratio
11.36
Forward P/E
-0.63
Price / Sales
99.49
Enterprise Value
$-0.61 M
EV / EBITDA
0.14
EV / Revenue
-8.48
Rating
None
Target Price
—
EPS Forecast (FY)
—
Pros
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Atara Biotherapeutics, Inc. | $4.99 | 1.29 | $42.24 M | — | 674.99% | -48.15% | $19.14 / $3.92 | $-5.26 |
| 2. | Evaxion A/S | $4.49 | — | $37.11 M | — | -38.23% | -1% | $12.15 / $1.25 | $2.04 |
| 3. | Rhythm Pharmaceuticals, Inc. | $87.72 | — | $5.99 B | — | -51.31% | -90.45% | $122.2 / $55.31 | $2.07 |
| 4. | Maze Therapeutics, Inc. | $26.84 | — | $1.4 B | — | -38.15% | -47.52% | $53.65 / $7.16 | $7.2 |
| 5. | Opus Genetics, Inc. | $5.54 | — | $394.17 M | — | -90.9% | -2.42% | $5.81 / $0.71 | $0.22 |
| 6. | Enveric Biosciences, Inc. | $3.65 | — | $3.44 M | — | -210.04% | -3.04% | $17.84 / $1.71 | $3.94 |
| 7. | MapLight Therapeutics, Inc. | $28.34 | — | $1.28 B | — | -36.5% | -56.19% | $31.13 / $12.24 | $10.41 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0.02 M | 0.02 M | 0.02 M | 0.02 M | 0.02 M | — |
| Operating Profit | -0.79 M | -1.15 M | -1.25 M | -1.09 M | -1.81 M | — |
| Net Profit | -0.88 M | -1.11 M | -1.2 M | -1.03 M | -1.73 M | — |
| EPS in Rs | -0.05 | -0.07 | -0.07 | -0.06 | -0.11 | -0.22 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0.07 M | 0.07 M | 0.07 M | 0.07 M |
| Operating Profit | -4.28 M | -4.71 M | -3.86 M | -3.65 M |
| Net Profit | -4.23 M | -4.39 M | -3.7 M | -3.91 M |
| EPS in Rs | -0.26 | -0.27 | -0.23 | -0.24 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 7.61 M | 7.41 M | 7.75 M | 11.64 M |
| Total Liabilities | 1.3 M | 2.38 M | 1.57 M | 1.3 M |
| Equity | 6.31 M | 5.03 M | 6.18 M | 10.34 M |
| Current Assets | 7.39 M | 7.11 M | 7.68 M | 11.57 M |
| Current Liabilities | 0.65 M | 1.66 M | 0.78 M | 0.44 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -4.66 M | -3.83 M | -3.22 M | -3.5 M |
| Investing CF | 0.64 M | 0.97 M | -4.15 M | 0.09 M |
| Financing CF | 4.86 M | 3.24 M | -0.47 M | 4.94 M |
| Free CF | -5.24 M | -3.83 M | -3.22 M | -3.5 M |
| Capex | -0.57 M | — | — | — |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 0% | 0% | — | — |
| Earnings Growth % | -18.7% | 5.32% | — | — |
| Profit Margin % | -6092.59% | -5132.57% | -5420.86% | — |
| Operating Margin % | -6526.44% | -5347.41% | -5059.02% | — |
| Gross Margin % | 91.9% | 91.9% | 91.9% | — |
| EBITDA Margin % | -6076.96% | -5029.28% | -5416.2% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2022-09-15 | 1:0.02 |